^
Association details:
Biomarker:FGFR2 fusion
Cancer:Gastric Cancer
Drug:Truseltiq (infigratinib) (FGFR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Cholangiocarcinoma)
New
Excerpt:
TRUSELTIQ is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.
Evidence Level:
Sensitive: D – Preclinical
New
Source:
Title:

Anti-tumor activity of infigratinib, a potent and selective inhibitor of FGFR1, FGFR2 and FGFR3, in FGFR fusion-positive cholangiocarcinoma and other solid tumors

Excerpt:
Infigratinib has also demonstrated efficacy in FGFR fusion+ PDX models of cholangiocarcinoma, breast cancer, liver cancer, gastric cancer and glioma.